Medication & Safety
Return and Refund Policy: What to Check Before You Buy
A clear return and refund policy tells you a lot about a seller before anything goes wrong. Here is what to check before...
Eligibility is not a single number that applies uniformly across every age. It shifts at both ends of the spectrum, for genuinely different reasons at each end.
Adolescents
Some GLP-1 medications have specific adolescent indications in certain regulatory settings, generally from age 12, for severe obesity with significant comorbidity.
This is a specialist decision, not a general prescribing one. It requires paediatric endocrinology or a similarly qualified specialist, careful assessment of growth and development, and family involvement throughout.
The considerations differ from adults in specific ways. Growth is still occurring, and any intervention needs to account for that. Psychological readiness and family context matter enormously at this age. And the long-term safety data in this age group is considerably thinner than in adults, given how much more recently these medications have been used in younger populations.
This is not a decision to pursue outside specialist care, and it is not something a general weight loss product, including any supplement, should be directed toward. Adolescent obesity management belongs with paediatric specialists.
Adults in general
The standard eligibility framework, BMI 30 or above or 27 with a weight-related condition, applies broadly across adulthood without an upper limit written into it.
Older adults
Not excluded, but the assessment genuinely differs.
The evidence includes older adults. SELECT enrolled adults aged 45 and above, demonstrating cardiovascular benefit in that population specifically.
Dehydration risk is higher. Older adults have reduced thirst sensation at baseline, and this compounds with the appetite-related thirst reduction covered elsewhere in this series. Monitoring fluid status matters more.
Muscle preservation matters more, not less. Sarcopenia, age-related muscle loss, is already occurring. Any additional muscle loss from an unsupported calorie deficit compounds a process already underway, with functional consequences including fall risk and reduced independence.
Polypharmacy increases interaction risk. Older adults frequently take multiple medications, increasing the number of interactions covered in our guide to drug interactions with GLP-1 medication that need reviewing.
Frailty assessment matters alongside BMI. A BMI that would indicate obesity in a younger adult may carry different implications in someone who is also becoming frail, where aggressive weight loss could be counterproductive.
None of this means older adults should avoid these treatments. It means the assessment needs to weigh these factors specifically, with resistance training and protein intake mattering even more than in younger adults.
Why there is no simple upper cutoff
Unlike the reasonably defined lower boundary for adolescent use, there is no clean upper age limit, because the relevant factor is not age itself but the accumulation of other conditions that correlates with it.
A healthy, active 70-year-old with obesity and no other significant conditions is a different case from a frail 70-year-old with multiple comorbidities and reduced mobility, even though both are the same age.
This is why the screening process this series has covered throughout, rather than age alone, is what actually determines appropriateness.
The Pakistan-specific consideration
WHO's obesity fact sheet covers the health stakes generally, but the practical situation in Pakistan adds a layer relevant to age.
For older adults specifically, the supply and verification problems covered throughout this series regarding informal import are compounded by the polypharmacy issue above. An older adult self-sourcing medication without any review is combining the general market risks with the specific interaction risks their medication list carries.
Where structured review matters most
Age-related factors, adolescent status requiring specialist referral, dehydration risk, muscle preservation priorities, and polypharmacy interactions, are all things a proper review should account for rather than treating every adult applicant identically.
Physician-reviewed sublingual drops include assessment of these factors as part of the review before dispatch. METASLIM™ is a physician-reviewed sublingual supplement working on the GLP-1 appetite pathway, and it is not intended for use in anyone under 18, consistent with the specialist-only nature of adolescent obesity management.
Our guide to who should not take GLP-1 medication covers the broader contraindication list alongside these age-specific considerations.
The summary
Adolescent use requires specialist paediatric assessment and is not a general prescribing decision, given ongoing growth and thinner safety data in this age group.
Standard adult eligibility has no upper age limit written into it, and SELECT specifically included adults aged 45 and above.
Older adults face higher dehydration risk given reduced baseline thirst sensation, and muscle preservation matters more given underlying sarcopenia already in progress.
Polypharmacy in older adults increases the number of potential medication interactions requiring review.
There is no clean upper cutoff, because the relevant factor is accumulated conditions rather than age itself.
See if you qualify for the program with age-related factors assessed as part of the review.
This article is for informational purposes only and does not constitute medical advice. Consult a qualified physician before starting any weight loss program, medication, or supplement.